Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Bayuk

Allergy & Immunology Northampton, MA Doctor of Osteopathy

NPI 1588637102 CMS profile 253658

269 Locust St, Suite 201, Northampton, MA 01062

Open in the dashboard

General payments

$419,546

1,472 records reported · program years 2019–2025

Research payments

$1,750

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Bayuk of Northampton, MA is reported in the CMS Open Payments database as having received $419,546 across 1,472 general payments and $1,750 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65,630 236
2024 General $39,360 218
2023 General $83,909 271
2022 General $78,267 227
2021 General $58,255 197
2020 General $32,397 138
2020 Research $1,750 1
2019 General $61,729 185

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Bayuk
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jonathan Bayuk were reported at $65,630. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jonathan Bayuk Allergy & Immunology median Middle half National median
2019 $61,729 $594 $163–$1,512 $163
2020 $32,397 $426 $106–$1,233 $114
2021 $58,255 $638 $157–$1,708 $132
2022 $78,267 $790 $205–$1,961 $149
2023 $83,909 $852 $220–$2,147 $160
2024 $39,360 $865 $203–$2,267 $164
2025 $65,630 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $99,435 276 payments
  2. Genzyme Corporation $55,575 83 payments
  3. Regeneron Healthcare Solutions, Inc. $34,905 112 payments
  4. Pfizer Inc. $33,905 150 payments
  5. Galderma Laboratories, L.P. $33,610 24 payments
  6. Pharming Healthcare, Inc. $28,258 58 payments
  7. GlaxoSmithKline, LLC. $27,173 132 payments
  8. Amgen Inc. $19,807 56 payments
  9. Grifols USA, LLC $17,962 40 payments
  10. Novartis Pharmaceuticals Corporation $14,799 98 payments
  11. Other $54,116 443 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $311,964 165 payments
  2. Travel and Lodging $37,291 72 payments
  3. Food and Beverage $27,983 1,195 payments
  4. Consulting Fee $25,636 18 payments
  5. Honoraria $16,334 8 payments
  6. Education $338 14 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $51,387 84 payments
  2. TEZSPIRE Respiratory $39,377 61 payments
  3. DUPIXENT Inflammation And Immunology $34,713 103 payments
  4. FASENRA Respiratory $33,985 91 payments
  5. NEMLUVIO $33,610 24 payments
  6. RUCONEST $28,258 58 payments
  7. CIBINQO $26,958 72 payments
  8. FASENRA Respiratory $20,678 54 payments
  9. Xembify $20,084 39 payments
  10. TEZSPIRE Inflammation $19,758 54 payments
  11. Other $101,347 918 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,750 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

1,936

Median for Allergy/ Immunology: 449

Drug cost

$2,803,666

Median for Allergy/ Immunology: $169,700

Branded share of claims

56.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 123 $493,309
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 39 $420,560
Dupixent Syringe Dupilumab Brand 79 $307,409
Dupixent Pen Dupilumab Brand 80 $302,834
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 20 $269,050
Gammagard S-D Immun Glob G/Gly/Gluc/Iga 0-50 Brand 23 $230,911
Fasenra Pen Benralizumab Brand 27 $153,549
Nucala Mepolizumab Brand 31 $120,410
Fasenra Benralizumab Brand 17 $97,296
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 16 $92,325

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$260,750

Of which drugs: $308

Medicare patients

929

Average age 70

Services billed

20,554

698 women, 231 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 47%
Depression 29%
Osteoporosis 21%
Diabetes 17%
Chronic kidney disease 13%
COPD 13%
Ischemic heart disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 212 $159
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 990 $102

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
$9,179 — —
RUCONEST
$7,503 — —
FASENRA
$6,490 44 —
Xembify
$4,755 — —
TEZSPIRE
$3,938 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

1,473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record